Lerebours, Florence
Pulido, Marina
Fourme, Emmanuelle
Debled, Marc
Becette, Véronique
Bonnefoi, Hervé
Rivera, Sofia
MacGrogan, Gaetan
Mouret-Reynier, Marie-Ange
de Lara, Christine Tunon
Pierga, Jean-Yves
Breton-Callu, Christel
Venat-Bouvet, Laurence
Mathoulin-Pélissier, Simone
de la Motte rouge, Thibault
Dalenc, Florence
Sigal, Brigitte
Bachelot, Thomas
Lemonnier, Jérôme
Quenel-Tueux, Nathalie
Article History
Received: 25 March 2019
Revised: 20 December 2019
Accepted: 17 January 2020
First Online: 31 January 2020
Ethics approval and consent to participate
: All patients provided written informed consent, and the Ethical Committee—Ile de France VIII approved the CARMINA study, and the Ethical Committee Sud-Ouest et Outre-Mer III approved the HORGEN study. The studies were performed in accordance with the Declaration of Helsinki, EU clinical trial directives (2001/20/CE) and Good Clinical Practice guidelines.
: N/A
: Data supporting the results reported in the article can be found at UNICANCER datacenter in Montpellier, France for CARMINA02 study, and in Bergonié Institute, Bordeaux, France for HORGEN study. Data analysis has been performed in the Clinical and Epidemiological Research Unit, Institut Bergonié, INSERM CIC 14.01, Bordeaux, France.
: J.Y.P. is a member of the BJC editorial board. The other authors made no disclosures.
: With the financial support of AstraZeneca, the funding source had no role in the design of the studies, the collection, analysis or interpretation of the data or in the writing of the paper. CARMINA02 study was sponsored by UNICANCER; HORGEN study was sponsored by Institut Bergonié.